Online first
Research paper
Published online: 2024-11-19

open access

Page views 97
Article views/downloads 26
Get Citation

Connect on Social Media

Connect on Social Media

Efficacy and Safety of Oral Semaglutide in Managing Type 2 Diabetes in India: A Real-World Study

Saswati Ray1, Aparajita Ray1, Siddhartha Goutam2, Asis Mitra3

Abstract

Objective: To examine the effectiveness, safety, and tolerability of oral semaglutide, the only tablet that delivers glucagon-like peptide-1 (GLP-1) receptor agonists (RA) orally, in a real-world setting, for Indian patients with type 2 diabetes (T2D). Materials and methods: Medical data were included for patients with uncontrolled T2D. Glycated hemoglobin (HbA1c) in the laboratory was the main outcome measure. Hypoglycemia, weight, and fasting plasma glucose (FPG) were used as secondary metrics. Results: The weight reduction was significant during the first 6 months, then it was in a plateau phase, and again it went up from 12 months until the end of the study period. The mean FPG dropped from 156.4 mg/dL to 103.8 mg/dL, and the mean postprandial blood glucose (PPPG) changed from 248.9 mg/dL to 169.8 mg/dL over the treatment period. Similarly, the HbA1c level changed from 8.6% to 7.0%. A small percentage of patients had hypoglycemia: 0.5% of patients at T6, 1.1% at T12, and 1.4% reported having a moderate episode (54–70 mg/dL); one incident of severe hypoglycemia was observed at T12. Conclusions: For people with T2D, oral semaglutide therapy significantly reduced blood sugar levels and helped them lose weight.

Article available in PDF format

View PDF Download PDF file

References

  1. Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021; 69(11): 2932–2938.
  2. Pradeepa R, Mohan V. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr. 2017; 71(7): 816–824.
  3. Kaveeshwar S, Cornvall J. The current state of diabetes mellitus in India. Australas Med J. 2014; 7(1): 45–48.
  4. Buckley S, Bækdal T, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018; 10(467).
  5. Gallwitz B, Giorgino F. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. Front Endocrinol (Lausanne). 2021; 12: 645507.
  6. Lavernia F, Blonde L. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. Postgrad Med. 2020; 132(sup2): 15–25.
  7. Aroda V, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019; 42(9): 1724–1732.
  8. Rodbard HW, Rosenstock J, Canani L, et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019; 42(12): 2272–2281.
  9. Pratley R, Aroda V, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018; 6(4): 275–286.
  10. Guzauskas GF, Rind DM, Fazioli K, et al. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. J Manag Care Spec Pharm. 2021; 27(4): 455–468.
  11. Aroda VR, Faurby M, Lophaven S, et al. Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study. Diabetes Obes Metab. 2021; 23(9): 2177–2182.
  12. Yanai H, Hakoshima M, Adachi H, et al. Editorial Office, Editorial Office, Editorial Office, Editorial Office, Editorial Office. A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes. Cardiol Res. 2022; 13(5): 303–308.
  13. Blonde L, Khunti K, Harris S, et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther. 2018; 35(11): 1763–1774.
  14. Anjana R, Unnikrishnan R, Deepa M, et al. Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study. Lancet Diabetes Endocrinol. 2022; 10(6): 430–441.
  15. Chawla R, Madhu SV, Makkar BM, et al. RSSDI-ESI Consensus Group. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. Indian J Endocrinol Metab. 2020; 24(1): 1–122.
  16. Yamada H, Yoshida M, Funazaki S, et al. Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings. J Cardiovasc Dev Dis. 2023; 10(4): 176.
  17. Reichert S, Amadid H, Braae U, et al. Clinical outcomes associated with the use of oral semaglutide in an adult population with type 2 diabetes in Canada: a prospective real-world study (PIONEER REAL Canada). Canadian Journal of Diabetes. 2023; 47(7): S96–S97.
  18. Wing R, Marcus M, Epstein L, et al. Type II Diabetic Subjects Lose Less Weight Than Their Overweight Nondiabetic Spouses. Diabetes Care. 1987; 10(5): 563–566.
  19. Evert AB, Franz MJ. Why Weight Loss Maintenance Is Difficult. Diabetes Spectr. 2017; 30(3): 153–156.
  20. Holst JJ, Madsbad S. Semaglutide seems to be more effective the other GLP-1Ras. Ann Transl Med. 2017; 5(24): 505.
  21. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014; 124(10): 4473–4488.
  22. Muskiet MHA, Tonneijck L, Smits M, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017; 13(10): 605–628.
  23. Mosenzon O, Blicher TM, Rosenlund S, et al. PIONEER 5 Investigators. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019; 7(7): 515–527.
  24. Mima A, Qi W, King GL. Implications of Treatment That Target Protective Mechanisms Against Diabetic Nephropathy. Semin Nephrol. 2012; 32(5): 471–478.
  25. Perkovic V, Tuttle KR, Rossing P, et al. FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024; 391(2): 109–121.
  26. Tuttle KR, Lakshmanan MC, Rayner B, et al. Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7). Diabetes Obes Metabol. 2019; 21(6): 1493–1497.
  27. Heerspink HJL, Sattar N, Pavo I, et al. Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis. Diabetes Care. 2022; 46(8): 1501–1506.
  28. Sun F, Chai S, Yu K, et al. Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Technol Ther. 2015; 17(1): 35–42.
  29. Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis. Diabetes Obesi Metab. 2017; 19(4): 524–536.